Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q3 2022 vs. Q2 2022
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 23 | 23 | 0 |
| Shares | 19.9M | 20.3M | +412.4K (+2.1%) |
| Value | $37.5M | $15.7M | −$21.7M (−58.0%) |
New holders (5)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Fernwood Investment Management, LLC | 297,080 | $234.0K | 0.10% |
| Renaissance Technologies LLC | 28,600 | $23.0K | 0.00% |
| Virtu Financial LLC | 14,717 | $12.0K | 0.00% |
| Ionic Capital Management LLC | 100 | $0 | 0.00% |
| Simplex Trading, LLC | 1,003 | $0 | 0.00% |
Sold out (5)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| BIT Capital GmbH | 30,000 | $57.9K |
| Two Sigma Securities, LLC | 16,832 | $32.0K |
| Goldman Sachs Group Inc | 10,269 | $20.0K |
| Penserra Capital Management LLC | 6,706 | $12.0K |
| Citigroup Inc | 195 | $0 |